NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
104 trialsNCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05628883 2026-04-02
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04052334 2026-02-20
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01005745 2025-12-19
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT01701674 2025-12-19
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT05080790 2025-08-17
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT00994643 2025-04-30
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Phase 2 Completed
NCT02278887 2025-03-10
TIL
The Netherlands Cancer Institute
Phase 3 Completed
NCT03475134 2025-02-11
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT04011033 2024-10-08
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Beijing YouAn Hospital
Phase 2 Completed
NCT03175679 2024-09-19
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Beijing YouAn Hospital
Phase 1 Completed
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT04165967 2024-04-10
BaseTIL
University Hospital, Basel, Switzerland
Phase 1 Completed
NCT03850691 2024-01-17
Radiation and Combination Immunotherapy for Melanoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00101101 2023-08-22
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03215810 2023-07-24
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01288963 2023-06-15
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Beth Israel Deaconess Medical Center
Completed
NCT04630769 2023-04-03
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03287674 2023-03-01
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Completed
NCT02414945 2023-01-10
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
Phase 1/2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT04327037 2022-03-02
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Phase 1 Completed
NCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02989714 2021-07-13
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT01662804 2021-05-27
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03213964 2021-03-12
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02763475 2020-10-05
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
Phase 2 Completed
NCT03158935 2020-08-14
ACTIVATE
University Health Network, Toronto
Phase 1 Completed
NCT01370213 2020-05-13
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03224871 2020-04-07
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
University of California, Davis
Phase EARLY_PHASE1 Completed
NCT02354690 2020-03-23
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT02316964 2020-03-09
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01266603 2020-02-19
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00002787 2019-05-06
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT01124734 2019-02-12
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Milton S. Hershey Medical Center
Phase 2 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00352885 2018-09-14
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
Emory University
Phase 4 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00539695 2018-05-04
IL2 for GVHD
Baylor College of Medicine
Phase 2 Completed
NCT00952237 2018-04-25
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT01181258 2018-02-06
MT2009-15
Masonic Cancer Center, University of Minnesota
Phase 2 Completed